Stockreport

Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates [Yahoo! Finance]

Trevi Therapeutics, Inc.  (TRVI) 
PDF Topline results continue to be expected in the first half of 2025 for the Phase 2b CORAL trial in chronic cough in IPF IND cleared with the FDA for planned Phase 1b t [Read more]